Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Cardiology Reports
Published in: Current Cardiology Reports 3/2010

01-05-2010

Use of Multiple Biomarkers in Heart Failure

Author: Larry A. Allen

Published in: Current Cardiology Reports | Issue 3/2010

Login to get access

Abstract

Biomarkers are becoming increasingly available for clinical use, particularly in the care of patients with heart failure. For health care providers, a major difficulty is how to interpret and apply these increasing amounts of diagnostic and prognostic information. Consequently, the scientific challenge is evolving from the discovery of biomarkers to the selection and validation of select panels of clinically useful markers that balance performance and practicality. Optimal combinations of biomarkers will vary based on the intended use (eg, diagnosis vs prognosis). The final goal must be to generate more actionable knowledge that improves patient management and outcomes, rather than merely creating greater complexity. Here we conceptually define multiple biomarker strategies, provide examples of emerging biomarker panels used in the care of patients with heart failure, and address key statistical and clinical issues for this rapidly evolving field.
Literature
1.
Biomarker Definitions Working Group: Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther 2001, 69:89–95.CrossRef
2.
Vasan RS: Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 2006, 113:2335–2362.CrossRefPubMed
3.
Mark DB, Felker GM: B-type natriuretic peptide—a biomarker for all seasons? N Engl J Med 2004, 350:718–720.CrossRefPubMed
4.
Allen LA, Hernandez AF, O’Connor CM, et al.: End points for clinical trials in acute heart failure syndromes. J Am Coll Cardiol 2009, 53:2248–2258.CrossRefPubMed
5.
Donahue MP, Marchuk DA, Rockman HA: Redefining heart failure: the utility of genomics. J Am Coll Cardiol 2006, 48:1289–1298.CrossRefPubMed
6.
Arab S, Gramolini AO, Ping P, et al.: Cardiovascular proteomics: tools to develop novel biomarkers and potential applications. J Am Coll Cardiol 2006, 48:1733–1741.CrossRefPubMed
7.
• Hlatky MA, Greenland P, Arnett DK, et al.: Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 2009, 119:2408–2416. This is an expert summary of current concepts and standards for critical appraisal of risk assessment in cardiovascular disease CrossRefPubMed
8.
• McGeechan K, Macaskill P, Irwig L, et al.: Assessing new biomarkers and predictive models for use in clinical practice: a clinician’s guide. Arch Intern Med 2008, 168:2304–2310. This paper proposes a framework for how to assess the clinical use of new biomarkers.CrossRefPubMed
9.
• Braunwald E: Biomarkers in heart failure. N Engl J Med 2008, 358:2148–2159. This is a general review of existing and emerging biomarkers in heart failure.CrossRefPubMed
10.
Lainscak M, Anker MS, von Haehling S, et al.: Biomarkers for chronic heart failure : diagnostic, prognostic, and therapeutic challenges. Herz 2009, 34:589–593.CrossRefPubMed
11.
Allen LA, Michael Felker G: Multi-marker strategies in heart failure: clinical and statistical approaches. Heart Fail Rev 2009 May 3 [Epub ahead of print].
12.
Morrow DA, Braunwald E: Future of biomarkers in acute coronary syndromes: moving toward a multimarker strategy. Circulation 2003, 108:250–252.CrossRefPubMed
13.
Fonarow GC, Adams KF Jr, Abraham WT, et al.: Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA 2005, 293:572–580.CrossRefPubMed
14.
Newby LK, Storrow AB, Gibler WB, et al.: Bedside multimarker testing for risk stratification in chest pain units: the chest pain evaluation by creatine kinase-MB, myoglobin, and troponin I (CHECKMATE) study. Circulation 2001, 103:1832–1837.PubMed
15.
James SK, Lindback J, Tilly J, et al.: Troponin-T and N-terminal pro-B-type natriuretic peptide predict mortality benefit from coronary revascularization in acute coronary syndromes: a GUSTO-IV substudy. J Am Coll Cardiol 2006, 48:1146–1154.CrossRefPubMed
16.
Sabatine MS, Morrow DA, de Lemos JA, et al.: Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation 2002, 105:1760–1763.CrossRefPubMed
17.
Westerhout CM, Fu Y, Lauer MS, et al.: Short-and long-term risk stratification in acute coronary syndromes: the added value of quantitative ST-segment depression and multiple biomarkers. J Am Coll Cardiol 2006, 48:939–947.CrossRefPubMed
18.
Wilson PW, D'Agostino RB, Levy D, et al.: Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97:1837–1847.PubMed
19.
Ridker PM, Rifai N, Rose L, et al.: Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002, 347:1557–1565.CrossRefPubMed
20.
Ralli S, Horwich TB, Fonarow GC: Relationship between anemia, cardiac troponin I, and B-type natriuretic peptide levels and mortality in patients with advanced heart failure. Am Heart J 2005, 150:1220–1227.CrossRefPubMed
21.
van Kimmenade RR, Januzzi JL, Jr., Baggish AL, et al.: Amino-terminal pro-brain natriuretic peptide, renal function, and outcomes in acute heart failure: redefining the cardiorenal interaction? J Am Coll Cardiol 2006, 48:1621–1627.CrossRefPubMed
22.
Anand IS, Rector T, Latini R, et al.: Do biomarkers add prognostic information to routine measures of the severity of heart failure? J Am Coll Cardiol 2006, 7(4A):A66–A67.
23.
Latini R, Masson S, Anand IS, et al.: Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation 2007, 16:1242–1249.CrossRef
24.
Dunlay SM, Gerber Y, Weston SA, et al.: Prognostic value of biomarkers in heart failure: application of novel methods in the community. Circ Heart Fail 2009, 2:393–400.CrossRefPubMed
25.
Levy WC, Mozaffarian D, Linker DT, et al.: The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation 2006, 113:1424–1433.CrossRefPubMed
26.
Januzzi JL Jr, Peacock WF, Maisel AS, et al.: Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J Am Coll Cardiol 2007, 50:607–613.CrossRefPubMed
27.
28.
van Kimmenade RR, Januzzi JL Jr, Ellinor PT, et al.: Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 2006, 48:1217–1224.CrossRefPubMed
29.
Maisel AS, Krishnaswamy P, Nowak RM, et al.: Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002, 347:161–167.CrossRefPubMed
30.
Januzzi JL Jr, Camargo CA, Anwaruddin S, et al.: The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 2005, 95:948–954.CrossRefPubMed
31.
Steinhart B, Thorpe KE, Bayoumi AM, et al.: Improving the diagnosis of acute heart failure using a validated prediction model. J Am Coll Cardiol 2009, 54:1515–1521.CrossRefPubMed
32.
Felker GM, Hasselblad V, Hernandez AF, et al.: Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. Am Heart J 2009, 158:422–430.CrossRefPubMed
33.
Jessup M, Abraham WT, Casey DE, et al.: 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009, 119:1977–2016.CrossRefPubMed
34.
Deng MC, Eisen HJ, Mehra MR, et al.: Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling. Am J Transplant 2006, 6:150–160.CrossRefPubMed
35.
Paynter NP, Chasman DI, Pare G, et al.: Association between a literature-based genetic risk score and cardiovascular events in women. JAMA 2010, 303:631–637.CrossRefPubMed
36.
Diamond GA, Denton TA, Berman DS, et al.: Prior restraint: a bayesian perspective on the optimization of technology utilization for diagnosis of coronary artery disease. Am J Cardiol 1995, 76:82–86.CrossRefPubMed
37.
Kattan MW: Judging new markers by their ability to improve predictive accuracy. J Natl Cancer Inst 2003, 95:634–635.PubMedCrossRef
38.
Cook NR: Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 2007, 115:928–935.CrossRefPubMed
39.
Cook NR, Ridker PM: Advances in measuring the effect of individual predictors of cardiovascular risk: the role of reclassification measures. Ann Intern Med 2009, 150:795–802.PubMed
40.
Morrow DA, Antman EM, Charlesworth A, et al.: TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation 2000, 102:2031–2037.PubMed
41.
Felker GM, Leimberger JD, Califf RM, et al.: Risk stratification after hospitalization for decompensated heart failure. J Card Fail 2004, 10:460–466.CrossRefPubMed
42.
Aaronson KD, Schwartz JS, Chen TM, et al.: Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation 1997, 95:2660–2667.PubMed
43.
Atienza F, Martinez-Alzamora N, De Velasco JA, et al.: Risk stratification in heart failure using artificial neural networks. Proc AMIA Symp 2000:32–36.
44.
Ortiz J, Ghefter CG, Silva CE, et al.: One-year mortality prognosis in heart failure: a neural network approach based on echocardiographic data. J Am Coll Cardiol 1995, 26:1586–1593.CrossRefPubMed
45.
Metadata
Title
Use of Multiple Biomarkers in Heart Failure
Author
Larry A. Allen
Publication date
01-05-2010
Publisher
Current Science Inc.
Published in
Current Cardiology Reports / Issue 3/2010
Print ISSN: 1523-3782
Electronic ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-010-0109-6

Other articles of this Issue 3/2010

Current Cardiology Reports 3/2010 Go to the issue

ReviewPaper

Cardiac Rehabilitation in Heart Failure: A Brief Review and Recommendations

ReviewPaper

Left Ventricular Assist Devices and Other Devices for End-Stage Heart Failure: Utility of Echocardiography

ReviewPaper

Three-Dimensional Echocardiography and Mitral Valve Disease

ReviewPaper

Myocardial Ischemia in Patients with Diastolic Dysfunction and Heart Failure

ReviewPaper

Echocardiographic Quantification of Left Ventricular Mass: Prognostic Implications

ReviewPaper

Therapeutic Potential of microRNAs in Heart Failure